Table 5 Outcome in high-risk breast cancer patients treated with high-dose busulfan-melphalan thiotepa regimen supported with stem cell transplantation Forty-seven patients (68%) are alive ...

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...

Analysis was based on data available as of 15 August 1999. Patients received busulfan at 16 mg/kg in divided doses of 1 mg/kg every 6 h for 4 consecutive days (days −7 to −4 ...

The data suggested that the initial safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation. Updated data from the BEACON study ...

The patient’s death comes at a time when researchers across industry and academia are seeking less toxic alternatives to busulfan as a bone conditioning regimen, a crucial component of cell and ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

BEAM is also advancing its ESCAPE program, which aims to eliminate the need for busulfan conditioning in hematopoietic stem cell transplantation. This approach could potentially expand the ...

BEAM-101, a genetically modified cell therapy for sickle cell, is designed to turn on HbF to counteract mutated adult ...